Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do we have a clinically useful breast cancer risk reduction agent for healthy women?

Nature Clinical Practice Oncology volume 3, pages 650–651 (2006)Cite this article

boxed-textVogel VG et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 295: 2727–2741

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Fisher B et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388

    Article  CAS  Google Scholar 

  2. Cuzick J et al. (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296–300

    Article  CAS  Google Scholar 

  3. Ettinger B et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282: 637–645

    Article  CAS  Google Scholar 

  4. Martino S et al. (2004) Invasive breast cancer risk reduction in postmenopausal women with osteoporosis treated with raloxifene for 8 years: results from the continuing outcomes relevant to Evista® trial. J Natl Cancer Inst 96: 1751–1761

    Article  CAS  Google Scholar 

  5. Barrett-Connor E et al. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355: 125–137

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Emeritus Professor of Breast Oncology at the Institute of Cancer Research, London

    Trevor J Powles

  2. Lead Clinician and Consultant Breast Oncologist at Parkside Oncology Clinic, Wimbledon, UK

    Trevor J Powles

Authors
  1. Trevor J Powles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Trevor J Powles.

Ethics declarations

Competing interests

Professor Powles has received consultancy fees and lecture fees from Eli Lilly (less than $10,000 p.a.).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Powles, T. Do we have a clinically useful breast cancer risk reduction agent for healthy women?. Nat Rev Clin Oncol 3, 650–651 (2006). https://doi.org/10.1038/ncponc0661

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0661

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing